Pressure BioSciences, Inc. is engaged in the development and sale of high-pressure technology-based instruments, consumables, and services for the life sciences and other industries worldwide. The Company's segments include Industrial, Consumer and Parent. Its Industrial segment contains the Ultra Shear Technology (UltraShear or UST), BaroFold Technology (BaroFold), and Pressure Cycling Technology (PCT) Platforms. Its products include Barocyclers, Barocycler Accessories, External Pressure Calibration Device Kit, MicroTubes for Barocyclers, MicroTube Accessories for Barocyclers, BaroShear K45, HUB High Pressure Generators and Accessories, HP Cell From ISS, RF1700 Mini Ultra-High Pressure Pump, SHREDDER SG3 and SHREDDER Tubes, and Service Contracts. Its Consumer segment represents the activity of Uncle Budâ€™s. Uncle Budâ€™s offers products direct-to-consumer online and through retail chains. Uncle Budâ€™s is engaged in hemp seed oil, cannabidiol (CBD), and the health and wellness industry.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

Quotes

Date	Price	Change	Volume

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Delayed OTC Markets Other stock markets 15:36:57 2026-06-11 EDT			5-day change	1st Jan Change
0.001200 ^USD	0.00%		0.00%	+140.00%

25-02-07	Pressure BioSciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-09-06	Pressure BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Market Cap	143K 124K 114K 107K 201K 13.56M 203K 1.34M 524K 6.64M 538K 527K 23.01M	P/E Ratio 2022	-0.81x	P/E Ratio 2023	-0.22x
Enterprise Value	22.95M 19.78M 18.21M 17.1M 32.1M 2.17B 32.44M 215M 83.83M 1.06B 86.12M 84.29M 3.68B	EV / Sales 2022	21.1x	EV / Sales 2023	15.5x
Free-Float	99.27%	Yield 2022 *	-	Yield 2023	-

25-02-07	Pressure BioSciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-09-06	Pressure BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-06-25	Pressure BioSciences, Inc. Partners with Vita-Forte to Commercialize Highly Potent, Multi-Antioxidant, UST Nanoemulsion Oral Spray	CI
24-06-20	Pressure BioSciences, Inc. - Special Call
24-06-07	Pressure BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-06-06	Pressure BioSciences, Inc. Auditor Raises 'Going Concern' Doubt	CI
24-02-15	Pressure BioSciences, Inc. Completes Relocation into New Manufacturing Facility, Consolidating R&D with Expanded UltraShear Equipment Development and Contract Manufacturing	CI
24-02-05	CBH International LLC, Pressure BioSciences, Inc. - M&A Call
24-01-21	Pressure BioSciences, Inc. completed the acquisition of CBH International LLC.	CI
24-01-18	Pressure BioSciences, Inc. Receives Open Order Agreement from West Coast Manufacturing Partner	CI
24-01-10	Pressure BioSciences, Inc. entered into a definitive agreement to acquire CBH International LLC.	CI
24-01-04	Pressure BioSciences' BaroFold Platform Expected to Revolutionize Biopharmaceutical Production with Help from New Computational (AI/ML) Technologies	CI
23-12-12	Pressure BioSciences, Inc. Announces the Publication of Pivotal Scientific Study in the Critical Field of Food Safety	CI

24-06-18	Pressure BioSciences, Inc. to Host Business and Financial Update on Thursday, June 20th at 4:30pm ET	AQ
24-06-13	Pressure BioSciences, Inc. to Host Business and Financial Update on Wednesday, June 19th at 4:30pm ET	AQ
24-04-11	Uncle Bud’s Health and Wellness to Expand New Premium Collection with Novel Products for Sleep, Memory, Pain, Immunity, Feminine Hygiene, and Sexual Wellness	AQ
24-04-02	Pressure BioSciences’ Uncle Bud’s Subsidiary Reports Significant Demand for New UltraShear CBD Body Revive Spray – First Product in New “Premium Collection”	AQ
24-02-26	Uncle Bud's Health & Wellness Experiencing Powerful Growth One Month Following Acquisition by Pressure BioSciences, Inc.	AQ

Pressure BioSciences, Inc. Stock

Stocks

PBIO

US74112E2081

Advanced Medical Equipment & Technology

Valuation: Pressure BioSciences, Inc.

Chart: Pressure BioSciences, Inc.

Latest news : Pressure BioSciences, Inc.

Press Releases: Pressure BioSciences, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Pressure BioSciences, Inc.

Latest insider transactions

Other Advanced Medical Equipment & Technology

Financials

Company Profile

Quotes

Income Statement and Estimates

1 month	+100.00%
3 months	+140.00%
6 months	+100.00%
Current year	+140.00%

1 week	0		0
1 month	0		0
Current year	0		0.1
1 year	0		0.2
3 years	0		0.83
5 years	0		4.98
10 years	0		13.8

Manager	Title	Age	Since
Richard Schumacher CEO	Chief Executive Officer	75	2004-04-15
Alexander Lazarev CTO	Chief Tech/Sci/R&D Officer	61	2006-04-02
Edmund Ting CTO	Chief Tech/Sci/R&D Officer	72	2006-04-23

Director	Title	Age	Since
Richard Schumacher CHM	Chairman	75	1991-12-31
Jeffrey Peterson CHM	Chairman	70	2012-08-07
Michael Urdea BRD	Director/Board Member	73	2013-02-07

Date	Insider	Type	Main position	Quantity	% Market Cap.
24-09-26	Michael Urdea	Others	Director	14,429	0.0416%
24-09-26	Jeffrey Peterson	Others	Chairman	59,652	0.1719%
24-09-26	Alexander Lazarev	Others	Chief Technology Officer	18,863	0.0543%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PRESSURE BIOSCIENCES, INC.	0.00%	0.00%	-52.00%	-99.86%	51.56K
THERMO FISHER SCIENTIFIC, INC.	+0.18%	-3.93%	+17.18%	-11.66%	176B
INTUITIVE SURGICAL, INC.	+0.34%	-2.03%	-19.48%	+26.90%	148B
DANAHER CORPORATION	+0.49%	-3.39%	-9.49%	-24.72%	128B
BOSTON SCIENTIFIC CORPORATION	-0.05%	-4.59%	-53.97%	-14.00%	69.5B
EDWARDS LIFESCIENCES CORPORATION	+3.02%	+1.96%	+19.30%	-2.91%	49.68B
SIEMENS HEALTHINEERS AG	+0.97%	+0.60%	-23.33%	-33.14%	45.26B
AGILENT TECHNOLOGIES, INC.	-0.83%	-4.51%	+8.69%	+6.80%	36.88B
WATERS CORPORATION	+1.95%	-1.69%	+4.91%	+35.54%	35.13B
GE HEALTHCARE TECHNOLOGIES INC.	-1.47%	-3.35%	-12.43%	-18.88%	29.46B
Average	+0.47%	-0.82%	-12.06%	-13.59%	71.77B
Weighted average by Cap.	+0.46%	-0.65%	-6.67%	-4.08%

	2022	2023
Net sales	1.73M 1.49M 1.37M 1.29M 2.42M 164M 2.44M 16.22M 6.32M 80.07M 6.49M 6.35M 277M	1.98M 1.7M 1.57M 1.47M 2.77M 187M 2.8M 18.55M 7.23M 91.57M 7.42M 7.26M 317M
Net income	-16.08M -13.85M -12.76M -11.98M -22.49M -1.52B -22.73M -151M -58.73M -744M -60.33M -59.05M -2.58B	-29.31M -25.26M -23.26M -21.84M -41.01M -2.77B -41.44M -275M -107M -1.36B -110M -108M -4.7B
Net Debt	20.53M 17.69M 16.29M 15.29M 28.71M 1.94B 29.02M 192M 74.98M 950M 77.03M 75.4M 3.29B	22.8M 19.65M 18.1M 16.99M 31.9M 2.16B 32.24M 214M 83.31M 1.06B 85.58M 83.77M 3.66B